A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Model

A Randomised, Single-Blind, Placebo-Controlled, Crossover Study to Investigate the Effects of RIST4721, a Novel CXCR2 Inhibitor, on the Inflammatory Response in Healthy Male Subjects Using a Standardized Blister Model

A Randomised, Single-Blind, Placebo-Controlled, Crossover Study to Investigate the Effects of RIST4721, a Novel CXCR2 Inhibitor, on the Inflammatory Response in Healthy Male Subjects Using a Standardized Blister Model

Inclusion Criteria:

• Subject is male, with Fitzpatrick skin types 1 to 3
• Subject is aged between 18 to 55 years, inclusive
• Subject has a body mass index (BMI) of 18 to 32 kg/m2, inclusive
• Healthy as determined by a responsible physician, based on medical evaluation
• Must be willing to use birth control as indicated

Exclusion Criteria:

• Subject is known to have immune deficiency or is immunocompromised
• Subject has had a recent acute infection or chronic infection
• Subject has a known or suspected allergy or contraindications to cantharidin (blister induction method), RIST4721 or any component of the study drug
• Clinically relevant history of abnormal physical or mental health (including [but not limited to], neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder)